Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15908148 | 0.88 | ALDH1A1 (0.53) | ALDH1A1SIGMAR1KMT2AMEN1NPSR1 | |
| SCHEMBL20792927 | 0.88 | ALDH1A1 (0.53) | ALDH1A1SIGMAR1KMT2AMEN1NPSR1 | |
| SCHEMBL15105924 | 0.88 | CHRM3 (0.46) | ALDH1A1KMT2AMEN1NPSR1 | |
| SCHEMBL31575357 | 0.85 | ALDH1A1 (0.50) | ALDH1A1SIGMAR1KMT2AMEN1NPSR1 | |
| SCHEMBL26419124 | 0.82 | MEN1 (0.59) | ALDH1A1KMT2AMEN1NPSR1SMN1; SMN2 | |
| SCHEMBL22059743 | 0.81 | ALDH1A1 (0.49) | ALDH1A1KMT2AMEN1NPSR1NPC1 | |
| SCHEMBL23277976 | 0.78 | SIGMAR1 (0.46) | ALDH1A1SIGMAR1KMT2AMEN1NPSR1 | |
| SCHEMBL23277780 | 0.78 | ALDH1A1 (0.43) | ALDH1A1SIGMAR1KMT2AMEN1NPSR1 | |
| SCHEMBL15106385 | 0.77 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1SMN1; SMN2MAPK1 | |
| SCHEMBL24835778 | 0.76 | ALDH1A1 (0.43) | ALDH1A1SIGMAR1KMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | ALDH1A1 2654/4885SIGMAR1 899/4885KMT2A 1950/4885 |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | ALDH1A1 2654/4885SIGMAR1 899/4885KMT2A 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.